DelveInsight’s “Postoperative Pain Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Postoperative Pain pipeline landscapes.
The report comprises Postoperative Pain pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Postoperative Pain therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Postoperative Pain pipeline products.
Postoperative Pain Overview
Postoperative pain is a normal response to surgical intervention and is a cause of delayed recovery and discharge after surgery or any other operative procedure, which also leads to an increased risk of wound infection. Untreated pain led to reduced patient satisfaction and increased morbidity and mortality and places a burden on patient finances. It usually lasts less than 3–6 months, and it is directly related to soft tissue damage, and it gradually resolves as the injured tissues heal.
Some of the key takeaways from the Postoperative Pain Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Vivozon, Avenue Therapeutics, Taiwan Liposome Company, etc., are developing therapies for the treatment of Postoperative Pain.
-
Emerging therapies such as VVZ-149 Injections, IV Tramadol, TLC590 (ropivacaine with sustained-release delivery technology), are expected to have a significant impact on the Postoperative Pain market in the coming years.
Get an overview of pipeline landscape @ Postoperative Pain Clinical Trials Analysis
Postoperative Pain Pipeline Therapies along with Key Players:
-
VVZ-149 Injections: Vivozon
-
IV Tramadol: Avenue Therapeutics
-
TLC590 (ropivacaine with sustained-release delivery technology): Taiwan Liposome Company
Scope of Postoperative Pain Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Vivozon, Avenue Therapeutics, Taiwan Liposome Company, and others.
-
Pipeline Therapies: VVZ-149 Injections, IV Tramadol, TLC590 (ropivacaine with sustained-release delivery technology), and others.
Table of Contents
|
1 |
Postoperative Pain Report Introduction |
|
2 |
Postoperative Pain Executive Summary |
|
3 |
Postoperative Pain Overview |
|
4 |
Postoperative Pain- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Postoperative Pain Pipeline Therapeutics |
|
6 |
Postoperative Pain Late Stage Products (Phase II/III) |
|
7 |
Postoperative Pain Mid Stage Products (Phase II) |
|
8 |
Postoperative Pain Early Stage Products (Phase I) |
|
9 |
Postoperative Pain Preclinical Stage Products |
|
10 |
Postoperative Pain Therapeutics Assessment |
|
11 |
Postoperative Pain Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Postoperative Pain Key Companies |
|
14 |
Postoperative Pain Key Products |
|
15 |
Postoperative Pain Unmet Needs |
|
16 |
Postoperative Pain Market Drivers and Barriers |
|
17 |
Postoperative Pain Future Perspectives and Conclusion |
|
18 |
Postoperative Pain Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Postoperative Pain Drugs Pipeline Report.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/